Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
COMPASS Pathways Plc - American Depository Shares
(NQ:
CMPS
)
6.560
+0.010 (+0.15%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about COMPASS Pathways Plc - American Depository Shares
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Psychedelic Drug Stocks Dragged Down By 83% Collapse In SEEL Stock Price
↗
September 24, 2023
With the 82.6% collapse of Seelos Therapeutics (SEEL) last week, the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index declined by 13.0%, on average, and...
Via
Talk Markets
How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space
September 22, 2023
By Faith Ashmore, Benzinga
Via
TheNewswire.com
Topics
Artificial Intelligence
How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space
September 22, 2023
--News Direct--
Via
News Direct
Topics
Artificial Intelligence
One Year Into Kabir Nath’s Leadership, Compass Pathways’ (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing
September 19, 2023
By Faith Ashmore, Benzinga
Via
TheNewswire.com
The Latest Analyst Ratings for Compass Pathways
↗
August 22, 2023
Via
Benzinga
One Year Into Kabir Nath’s Leadership, Compass Pathways’ (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing
September 19, 2023
--News Direct--
Via
News Direct
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
September 19, 2023
EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Economy
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
↗
September 18, 2023
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next
Via
Benzinga
One Year Into Kabir Nath's Leadership, Compass Pathways' (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing
↗
September 18, 2023
Treatment-resistant depression, also referred to as TRD, is a subset of depression that poses significant challenges for clinicians, patients and those closest to patients. It is characterized by...
Via
Benzinga
4 Of The 6 Largest Psychedelic Compound-Based R & D Stocks Had A Good Week
↗
September 17, 2023
4 of the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index were up in price last week versus only 1 the previous week. The Index was up 2.4% for the week...
Via
Talk Markets
Swedish Foundation Supports Mental Health Innovation With New €3M Psychedelic Science Initiative
↗
September 13, 2023
The Norrsken Foundation, a non-profit impact ecosystem “connecting founders with the capital, knowledge and network they need to make saving the world their business,” is launching a $3.22 (&e
Via
Benzinga
What’s Spurring The Growth Of The Psychedelics Market – And How One Company Is Helping As Part Of The Vanguard In This Emerging Field
September 13, 2023
--News Direct--
Via
News Direct
Topics
Intellectual Property
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
↗
September 12, 2023
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.
Via
Benzinga
What's Spurring The Growth Of The Psychedelics Market – And How One Company Is Helping As Part Of The Vanguard In This Emerging Field
↗
September 12, 2023
In August, a group of well-known biotech institutional investors participated in an up to almost $300 million financing round for COMPASS Pathways (NASDAQ: CMPS), consisting of an initial investment of...
Via
Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
↗
September 11, 2023
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification
Via
Benzinga
Topics
Artificial Intelligence
6 Largest Psychedelic Compound-Based R & D Stocks In Decline
↗
September 10, 2023
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 2.6%, on average, this week and are now only up 6.5% YTD.
Via
Talk Markets
Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression
↗
September 06, 2023
COMPASS Pathways plc (NASDAQ: CMPS) shared the results from research on the potential of its novel AI technologies to support its proprietary COM
Via
Benzinga
Topics
Artificial Intelligence
6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week
↗
September 05, 2023
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were UP 3.9%, on average, last week and are now only UP 9.4% YTD.
Via
Talk Markets
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
↗
September 05, 2023
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Via
Benzinga
August Recap: Largest Psychedelic Compound-Based R & D Stocks Down 15%
↗
September 02, 2023
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 15.0%, on average, in August and are now only up 5.3% YTD.
Via
Talk Markets
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
↗
August 28, 2023
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials
Via
Benzinga
3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street
↗
August 26, 2023
These cutting-edge biotech stocks could deliver life-changing gains for early shareholders.
Via
The Motley Fool
6 Largest Psychedelic Compound-Based R&D Stocks Continued Downwards, On Average, This Week
↗
August 25, 2023
Only 2 of the 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were up this week.
Via
Talk Markets
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
↗
August 21, 2023
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds
Via
Benzinga
Topics
Cannabis
Economy
Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend
↗
August 20, 2023
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were down an average of 6% last week and are now down 17.2% MTD. We take a look at them in...
Via
Talk Markets
COMPASS' Securities Purchase Agreement Is Big News
↗
August 18, 2023
It’s still cannabis earnings season, but we’re also turning to look at some of the news from the psychedelics industry. ...
Via
Benzinga
Topics
Cannabis
Up To $285M In Financing: COMPASS Pathways' Private Placement Backed By 'Select Group' Of Investors
↗
August 16, 2023
Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select group of...
Via
Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
↗
August 14, 2023
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published
Via
Benzinga
So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index
↗
August 13, 2023
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD.
Via
Talk Markets
Atai's Q2 2023 Plus Clinical Data On Ibogaine-Opioid Study, Pipeline's Psilocybin, DMT, Ketamine & MDMA
↗
August 10, 2023
Atai Life Sciences (NASDAQ: ATAI) reported its consolidated, unaudited financial results for the second quarter 2023 ended June 30. Numbers show:
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit